Androgen Annihilation Strategy Prolongs rPFS in mCRPC Androgen Annihilation Strategy Prolongs rPFS in mCRPC

Adding apalutamide to standard care significantly slows progression of chemotherapy-naive metastatic castration-resistant prostate cancer, according to the final results of a phase 3 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news